Jones Elaine V 4

What Happened

• Elaine V. Jones, a director at CytomX Therapeutics (CTMX), was granted an award/derivative covering 59,000 shares on 2026-06-17. The reported acquisition price is $0.00, indicating this is an equity award/option grant rather than an open-market purchase or sale. No immediate cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (filed late; Form 4s are generally due within 2 business days).
• Nature of security: derivative (option/award) for 59,000 shares; reported price: $0.00.
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote (F1): 100% of the shares subject to the option vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting, assuming continuous service as a director until such vesting date.
• Filing timeliness: late filing (transaction on 6/17; filing on 6/22). Late filings are disclosure issues but do not themselves indicate trading intent.

Context

• This was a compensation-related award (an option/award grant) to a director, commonly used as retention or service-based pay. Because it is a derivative grant, the transaction does not reflect an immediate market purchase or sale and does not indicate an immediate change in her cash exposure to the stock.